Larimar Therapeutics, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for LRMR, updated each market day.
LRMR AI Sentiment
AI sees no strong directional signal for Larimar Therapeutics, Inc. Common Stock stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Larimar Therapeutics, Inc. Common Stock
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
Sector
Exchange
Market Cap
$528,764,149
Cap Tier
Employees
71
Headquarters
BALA CYNWYD, PA
Listed Since
May 29, 2020
Website
LRMR Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
LRMR Volatility
Larimar Therapeutics, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
